Hostname: page-component-7b9c58cd5d-9klzr Total loading time: 0 Render date: 2025-03-15T04:34:42.897Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Study of the Effectiveness of Trifluopromazine Hydrochloride

Published online by Cambridge University Press:  08 February 2018

J. G. Hegarty  and
A. R. Dabbs
J. G. Hegarty
Affiliation:
Oakwood Hospital, Maidstone, Kent
A. R. Dabbs
Affiliation:
Oakwood Hospital, Maidstone, Kent
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Vespral, chemically designated as 10-(3-dimethylaminopropyl-2-trifluoro-methyl)-phenothiazine hydrochloride, or trifluopromazine hydrochloride is a new ataractic drug which has only recently become available in this country. A clinical field trial with Vespral has been reported in a previous issue of this journal (1). It was then suggested that the drug was most effective in the treatment of psychotic disorders, schizophrenia in particular. The aim of this study was to evaluate, with some claim to objectivity, the effectiveness of the administration of trifluopromazine hydrochloride on the behaviour of a small population of chronic schizophrenic patients.

Type
Original Articles
Information
Journal of Mental Science , Volume 105 , Issue 440 , July 1959 , pp. 811 - 814
Copyright
Copyright © Royal College of Psychiatrists, 1959 

References

1. Hegarty, J. G., J. Ment. Sci., 1958, 104, 870–872.Google Scholar
2. Payne, R. W., Paper read to the International Congress of Psychiatry, 1957, Zurich, Schweiz. Z. Psychol. Anwend. To appear.Google Scholar
3. Bartlett, M. S., Suppl. J. R. Statis. Soc., 1936, 3, 68.Google Scholar
4. Anscombe, F. J., Biometric., 1948, 34, 246.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.